Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.

The primary endpoint occurred in 6.8% of patients treated with colchicine and in 9.6% of patients treated with placebo, representing a highly significant relative reduction of 31% (hazard ratio 0.69, CI 0.57–0.83; P < 0.001).

also in 132,142 other papers